HK1215170A1 - 治療精神分裂症的方法和組合物 - Google Patents

治療精神分裂症的方法和組合物

Info

Publication number
HK1215170A1
HK1215170A1 HK16103149.6A HK16103149A HK1215170A1 HK 1215170 A1 HK1215170 A1 HK 1215170A1 HK 16103149 A HK16103149 A HK 16103149A HK 1215170 A1 HK1215170 A1 HK 1215170A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treating schizophrenia
schizophrenia
treating
Prior art date
Application number
HK16103149.6A
Other languages
English (en)
Inventor
Michela Gallagher
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of HK1215170A1 publication Critical patent/HK1215170A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
HK16103149.6A 2012-11-14 2016-03-17 治療精神分裂症的方法和組合物 HK1215170A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261726440P 2012-11-14 2012-11-14
PCT/US2013/070144 WO2014078568A1 (en) 2012-11-14 2013-11-14 Methods and compositions for treating schizophrenia

Publications (1)

Publication Number Publication Date
HK1215170A1 true HK1215170A1 (zh) 2016-08-19

Family

ID=50731694

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103149.6A HK1215170A1 (zh) 2012-11-14 2016-03-17 治療精神分裂症的方法和組合物

Country Status (6)

Country Link
US (3) US10154988B2 (zh)
EP (2) EP2919788A4 (zh)
JP (2) JP6440625B2 (zh)
CA (1) CA2891122C (zh)
HK (1) HK1215170A1 (zh)
WO (1) WO2014078568A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
DK3431106T3 (da) * 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
KR101634440B1 (ko) 2014-08-21 2016-06-30 서울대학교산학협력단 AMPA 수용체 GluA1의 인산화 억제제를 포함하는 정신질환의 예방 또는 치료용 약학조성물
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US20190125725A1 (en) * 2016-05-12 2019-05-02 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
CN106109402A (zh) * 2016-07-20 2016-11-16 南通雅本化学有限公司 一种左乙拉西坦注射液
MX2019007391A (es) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
US11253173B1 (en) * 2017-05-30 2022-02-22 Verily Life Sciences Llc Digital characterization of movement to detect and monitor disorders
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US20230270753A1 (en) * 2020-07-10 2023-08-31 Agenebio, Inc. Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment

Family Cites Families (731)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US759A (en) 1838-05-30 Reacting watek-wheels
US5516A (en) 1848-04-18 Combining lantebns and lamps
US1015498A (en) 1911-03-01 1912-01-23 Edward L Kraus Folding-desk blackboard.
IT535124A (zh) 1952-09-20
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
GB1309692A (en) 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JP2000319257A (ja) 1969-01-06 2000-11-21 Eisai Co Ltd １−ベンジル−４−［（５，６−ジメトキシ−２−フルオロ−１−インダノン）−２−イル］メチルピペリジン
US3953603A (en) 1973-11-05 1976-04-27 Eli Lilly And Company Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
IT1045043B (it) 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
IT1075280B (it) 1977-02-11 1985-04-22 Isf Spa Procedimento per la preparazione di derivati pirrolidinici
BE864269A (fr) 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
ATE27T1 (de) 1978-05-08 1981-04-15 Ucb Sa Lactam-n-essigsaeuren und ihre amide, verfahren zu ihrer herstellung und heilmittel, die sie enthalten
US4654370A (en) 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4431649A (en) 1979-07-30 1984-02-14 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
US4352807A (en) 1979-07-30 1982-10-05 Pfizer Inc. Hexahydro-trans-pyridoindole neuroleptic agents
US4337250A (en) 1979-07-30 1982-06-29 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
US4465683A (en) 1979-09-14 1984-08-14 Mead Johnson & Company Anti-psychotic agents
US4254124A (en) 1979-09-24 1981-03-03 Mead Johnson & Company Antidepressant agent
US4372960A (en) 1980-12-12 1983-02-08 Warner-Lambert Company Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
US4427679A (en) 1981-01-16 1984-01-24 Pfizer Inc. Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
FR2515179A1 (fr) 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
US4415085A (en) 1981-12-21 1983-11-15 Eli Lilly And Company Dry pharmaceutical system
GR81301B (zh) 1982-09-07 1984-12-11 Lilly Co Eli
PT77267B (en) 1982-09-07 1986-03-21 Lilly Co Eli Improved process for preparing novel octahydrobenz <f> isoquinolines or compounds relating thereto
US4879391A (en) 1982-09-20 1989-11-07 Pfizer Inc. 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
US4476307A (en) 1982-09-20 1984-10-09 Pfizer Inc. Heteroylidene indolone compounds
US4977178A (en) 1982-09-20 1990-12-11 Pfizer Inc. Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
US4495187A (en) 1982-10-18 1985-01-22 Pfizer Inc. Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
IL67623A (en) 1983-01-05 1984-09-30 Teva Pharma 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
IL72381A (en) 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US4547501A (en) 1983-09-02 1985-10-15 Pfizer Inc. Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
US4599339A (en) 1983-09-26 1986-07-08 Eli Lilly And Company Use of pyrimido[4,5-g]quinolines in treating parkinsonism
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
US4605655A (en) 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US4668687A (en) 1984-07-23 1987-05-26 Bristol-Myers Company Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4593037A (en) 1984-07-26 1986-06-03 Pfizer Inc. 1,3-disubstituted piperidine compounds as neuroleptic agents
US4619930A (en) 1985-01-16 1986-10-28 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IL74497A (en) 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4656173A (en) 1985-04-24 1987-04-07 Bristol-Myers Company Antipsychotic benzisothiazole S-oxide compound
US4677104A (en) 1985-05-06 1987-06-30 Bristol-Myers Company Antipsychotic fused-ring pyridinylpiperazine derivatives
JPS6222785A (ja) 1985-07-23 1987-01-30 Sanwa Kagaku Kenkyusho:Kk 新規な２−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4757073A (en) 1986-09-30 1988-07-12 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
DD263531A5 (de) 1986-10-21 1989-01-04 ������@���Kk�� Verfahren zur herstellung von verbrueckten bicyclischen imidverbindungen
MX174210B (es) 1987-02-17 1994-04-28 Pfizer Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
IL85741A (en) 1987-03-17 1996-05-14 Hoechst Roussel Pharma Transformed Tetra-Hydroacridines Process for their preparation and pharmaceutical preparations containing A-amino-Tetra-Transformed Hydroacridines
DE3709230A1 (de) 1987-03-20 1988-10-06 Desitin Arzneimittel Gmbh Neues calciumsalz der valproinsaeure
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
US4784998A (en) 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
US5002955A (en) 1987-04-23 1991-03-26 Hoechst-Roussel Pharmaceuticals Inc. Fused heteroalkylene quinolinamines and use as cholinergic agents
ATE411026T1 (de) 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
US5187165A (en) 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
US4931447A (en) 1987-06-15 1990-06-05 Eli Lilly And Company Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPS6422883A (en) 1987-07-17 1989-01-25 Sanwa Kagaku Kenkyusho Co 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
DE3773926D1 (de) 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
US5364863A (en) 1987-09-08 1994-11-15 Eli Lilly And Company Specific 5-HT3 antagonists
IL87674A (en) 1987-09-08 1993-08-18 Lilly Co Eli Azabicycloalkyl esters and amides of heterocyclic acids, their preparation and pharmaceutical compositions containing them
US4880930A (en) 1987-11-30 1989-11-14 New James S Psychotropic acyclic amide derivatives
US4891375A (en) 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5001130A (en) 1988-02-18 1991-03-19 Bristol-Myers Company Psychotropic heterobicycloalkylpiperazine derivatives
US5238959A (en) 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
US5242911A (en) 1988-06-17 1993-09-07 Pfizer Inc. Bridged bicyclic imides as anxiolytics and antidepressants
WO1990002552A1 (en) 1988-09-16 1990-03-22 Pfizer Inc. Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
WO1990005525A1 (en) 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
WO1990006303A1 (en) 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
US4950658A (en) 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
IL93051A0 (en) 1989-01-17 1990-11-05 Hoffmann La Roche ((5-oxo-2-pyrrolidinyl)methyl)cyclohexaneacetamides,their preparation and pharmaceutical compositions containing them
WO1990007926A1 (en) 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
FR2643556B1 (fr) 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US4963689A (en) 1989-05-19 1990-10-16 Pfizer Inc. Heterocyclicguanidines as 5HT3 antagonists
US4914207A (en) 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
DE69021645T2 (de) 1989-05-19 1996-02-22 Hoechst Roussel Pharma N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5693668A (en) 1989-06-22 1997-12-02 Merrell Pharmaceuticals Inc. Acetylcholinesterase inhibitors
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
IT1231477B (it) 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5006525A (en) 1989-07-24 1991-04-09 Eli Lilly And Company Dopamine agonists method
US4999430A (en) 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
DE3927049A1 (de) 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
WO1991003467A1 (en) 1989-08-30 1991-03-21 Pfizer Inc. Benzazabicyclic carbamates as novel cholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
US5011841B1 (en) 1989-11-14 1994-09-06 Pfizer Treatment of depression
WO1991009844A1 (en) 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
NZ237241A (en) 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
US5043341A (en) 1990-04-11 1991-08-27 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ATE113947T1 (de) 1990-06-01 1994-11-15 Pfizer 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
US5102891A (en) 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
DE69106365T2 (de) 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
US5264442A (en) 1990-08-13 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
TW200462B (zh) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
DK0550635T3 (da) 1990-09-28 1995-09-04 Pfizer Cykliske forbindelser med kondeserede ringe, som er analoger til nitrogenholdige ikke-aromatiske het erocykliske forbindelser
US5578612A (en) 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
AU651637B2 (en) 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5147881A (en) 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
JP2965675B2 (ja) 1990-11-21 1999-10-18 エーザイ株式会社 （―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
TW197435B (zh) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
JPH04327532A (ja) 1991-01-31 1992-11-17 Bristol Myers Squibb Co 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
ATE115581T1 (de) 1991-03-01 1994-12-15 Pfizer 1-azabicyclo(3.2.2>nonan-3-aminderivate.
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
ES2188584T3 (es) 1991-03-28 2003-07-01 Eisai Co Ltd Derivados heterociclicos de amina.
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5817655A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5817656A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5104880A (en) 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
SK279285B6 (sk) 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5716965A (en) 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
FR2677019B1 (fr) 1991-05-27 1994-11-25 Pf Medicament Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
KR100214905B1 (ko) 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
ES2092113T3 (es) 1991-06-20 1996-11-16 Pfizer Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
TW202432B (zh) 1991-06-21 1993-03-21 Pfizer
FR2679555B1 (fr) 1991-07-25 1993-11-19 Fabre Medicament Pierre Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
AU665207B2 (en) 1991-07-29 1995-12-21 Warner-Lambert Company Quinazoline derivatives as acetylcholinesterase inhibitors
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
US5161533A (en) 1991-09-19 1992-11-10 Xomed-Treace Inc. Break-apart needle electrode system for monitoring facial EMG
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
CA2118936A1 (en) 1991-09-25 1993-04-01 Gene M. Bright Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines
CA2118704C (en) 1991-09-26 1997-01-21 John A. Lowe, Iii Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
TW263504B (zh) 1991-10-03 1995-11-21 Pfizer
EP0537993A1 (en) 1991-10-17 1993-04-21 Eli Lilly And Company Nicotinic activity of a series of arecolones and isoarecolones
US5710168A (en) 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
CA2324959C (en) 1991-11-12 2002-11-12 Pfizer Limited Phthalimido compounds as intermediates for producing substance p receptor antagonists
ES2143992T3 (es) 1991-11-25 2000-06-01 Pfizer Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas.
US5137894A (en) 1991-12-05 1992-08-11 New James S 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
US5622976A (en) 1991-12-31 1997-04-22 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
AU4275793A (en) 1992-02-25 1993-09-13 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
TW288010B (zh) 1992-03-05 1996-10-11 Pfizer
US5569662A (en) 1992-03-23 1996-10-29 Pfizer Inc. Quinuclidine derivatives as substance P antagonists
CA2133413C (en) 1992-04-07 2001-04-10 John Eugene Macor Indole derivatives as 5-ht1 antagonists
US6380233B1 (en) 1992-04-07 2002-04-30 Pfizer Inc Indole derivatives as 5-HT1 agonists
JP2544704B2 (ja) 1992-04-10 1996-10-16 フアイザー・インコーポレイテツド ５−ｈｔ▲下１▼アゴニストとしてのアシルアミノインド―ル誘導体
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
US5256664A (en) 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
US20050256162A1 (en) 1992-05-05 2005-11-17 Pfizer Inc Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
CA2134964C (en) 1992-05-18 1997-12-30 Manoj C. Desai Bridged aza-bicyclic derivatives as substance p antagonists
IT1254996B (it) 1992-06-25 1995-10-11 Mediolanum Farmaceutici Srl Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
CA2141051A1 (en) 1992-08-04 1994-02-17 Terry J. Rosen Substituted nitrogen-containing heterocycles
DK0655996T3 (da) 1992-08-19 2001-12-27 Pfizer Substituerede benzylamino-nitrogenholdige, ikke-aromatiske, heterocykliske forbindelser
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5440023A (en) 1992-09-18 1995-08-08 Beckman Instruments, Inc. Method for making valproic acid derivatives
US5604241A (en) 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
US5837711A (en) 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
TW251284B (zh) 1992-11-02 1995-07-11 Pfizer
US5498610A (en) 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
EP0668863B1 (en) 1992-11-12 1997-01-08 Pfizer Inc. Quinuclidine derivative as substance p antagonist
CA2150123C (en) 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
US6369074B1 (en) 1992-12-10 2002-04-09 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
EP0611769A1 (en) 1993-02-16 1994-08-24 Merrell Dow Pharmaceuticals Inc. Silylated acetylcholinesterase inhibitors
WO1994020476A1 (en) 1993-03-02 1994-09-15 Fujisawa Pharmaceutical Co., Ltd. Novel heterocyclic compound
US5688806A (en) 1993-03-04 1997-11-18 Pfizer Inc. Spiroazacyclic derivatives as substance P antagonists
CA2158457C (en) 1993-03-16 2001-04-17 Bertrand Leo Chenard Naphthalene derivatives
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
EP0627400A1 (en) 1993-06-04 1994-12-07 Merrell Dow Pharmaceuticals Inc. Aromatic acetylcholinesterase inhibitors
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
DK0708771T3 (da) 1993-07-15 1999-06-21 Pfizer Benzyloxyquinuclidiner som substans P antagonister
DK0716649T3 (da) 1993-08-31 1999-02-08 Pfizer 5-Arylindolderivater
WO1995007908A1 (en) 1993-09-17 1995-03-23 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
US6083943A (en) 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
GB9319732D0 (en) 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US5468733A (en) 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0737194B1 (en) 1993-12-29 1999-03-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
CZ284633B6 (cs) 1994-03-02 1999-01-13 Akzo Nobel N. V. Farmaceutický prostředek a použití trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolu pro výrobu farmaceutického prostředku
AU1884595A (en) 1994-04-29 1995-11-29 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
CN1056611C (zh) 1994-06-16 2000-09-20 美国辉瑞有限公司 吡唑并吡啶和吡咯并吡啶,其用途和用于制备它们的中间体
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
ES2169131T3 (es) 1994-06-29 2002-07-01 Pfizer Derivados de aril y heteroaril alcoxinaftaleno.
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
KR100224961B1 (ko) 1994-08-18 1999-10-15 디. 제이. 우드 신경보호성 3-(피페리디닐-1)-크로만-4,7-디올 및 1-(4-하이드로페닐)-2-(피페리디닐-1)-알칸올 유도체
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5627200A (en) 1994-09-26 1997-05-06 Pfizer Inc β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
WO1996010570A1 (en) 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
US5516759A (en) 1994-12-08 1996-05-14 Tap Holdings Inc. LHRH antagonists having lactam groups at the N-terminus
US5658590A (en) 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
JPH11503757A (ja) 1995-04-18 1999-03-30 イーライ・リリー・アンド・カンパニー ５−ｈｔ▲下７▼レセプターにおいて生理学的および病理学的機能を生じるエルゴリン化合物の使用方法
US5889010A (en) 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
US20010023248A1 (en) 1995-05-25 2001-09-20 Howard Harry R. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
ATE199552T1 (de) 1995-07-07 2001-03-15 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
MX9800589A (es) 1995-07-24 1998-04-30 Lilly Co Eli Tratamiento de desorden de la falta de atencion/hiperactividad.
US5696168A (en) 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
TW340842B (en) 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
IL115113A (en) 1995-08-31 2002-11-10 Israel State 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
AU717012B2 (en) 1995-11-17 2000-03-16 Merck & Co., Inc. Novel substituted aryl compounds useful as modulators of acetylcholine receptors
US5783584A (en) 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
PT780375E (pt) 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
IL125031A0 (en) 1995-12-22 1999-01-26 Lilly Co Eli Method for treating depression
US5625897A (en) 1996-01-11 1997-05-06 Park; Kelly R. Upper torso garment
AU1582197A (en) 1996-01-22 1997-08-11 Eli Lilly And Company Combinatorial process for preparing substituted indane libraries
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
TR199801797T2 (xx) 1996-03-11 1998-12-21 Eli Lilly And Company �ki kutuplu bozukluk tedavisi.
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
PT891332E (pt) 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
EA001485B1 (ru) 1996-03-29 2001-04-23 Пфайзер Инк. Производные бензил(иден)-лактамов, их получение и применение в качестве селективных (ант)агонистов рецепторов 5-htи/или 5-ht
DE69707659T2 (de) 1996-04-12 2002-05-08 Aventis Pharma Inc Isatinderivate als acetylcholinesterase-inhibitoren und analgetika
TR199802241T2 (zh) 1996-05-07 1999-02-22 Pfizer Inc.
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
EP1380298A3 (en) 1996-05-23 2004-04-07 Bristol-Myers Squibb Pharma Company Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation
DE69708968T2 (de) 1996-05-28 2002-04-25 Pfizer Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste
AU1153097A (en) 1996-06-07 1998-01-05 Eisai Co. Ltd. Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
CA2180703A1 (en) 1996-07-08 1998-01-09 Paul Marie Victor Gilis Fast-dissolving galanthamine hydrobromide tablet
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
RO121272B1 (ro) 1996-07-24 2007-02-28 The Du Pont Merck Pharmaceutical Company Azolotriazine şi pirimidine
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
ES2171838T3 (es) 1996-08-01 2002-09-16 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para el tratamiento del trastorno bipolar.
US6117890A (en) 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
US6043258A (en) 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
MX9706196A (es) 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
WO1998007431A1 (en) 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
KR100516088B1 (ko) 1996-09-23 2005-09-22 일라이 릴리 앤드 캄파니 올란자핀 이수화물 ｄ
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
IT1285801B1 (it) 1996-10-10 1998-06-24 Sigma Tau Ind Farmaceuti Procedimento migliorato per la preparazione dell'acido valproico
ATE326468T1 (de) 1996-10-30 2006-06-15 Pfizer Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie
WO1998030243A1 (en) 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
WO1998032733A1 (en) 1997-01-29 1998-07-30 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US6020335A (en) 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
ATE241358T1 (de) 1997-03-03 2003-06-15 Eisai Co Ltd Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
GB2323788B (en) 1997-04-02 1999-02-17 Bristol Myers Squibb Co Venting valve for ostomy bag
EA003528B1 (ru) 1997-04-04 2003-06-26 Пфайзер Продактс Инк. Производные никотинамида, их применение, фармацевтическая композиция, способ лечения и способ ингибирования изоферментов фдэ4 d
ZA982877B (en) 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
EP1009403A4 (en) 1997-04-11 2002-08-28 Lilly Co Eli METHOD FOR TREATING SCHIZOPHRENIA
AU6896098A (en) 1997-04-11 1998-11-11 Eli Lilly And Company Method for treating schizophrenia
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0884310B1 (en) 1997-06-09 2005-09-07 Pfizer Products Inc. Quinazolin-4-one ampa antagonists
US6627755B1 (en) 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
CA2297906A1 (en) 1997-07-22 1999-02-04 Bret Eugene Huff Pharmaceutical compounds
GB9716879D0 (en) 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
WO1999008672A1 (en) 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
IL125951A (en) 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
JP2001517628A (ja) 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE260896T1 (de) 1997-12-05 2004-03-15 Eisai Co Ltd Donepezil polykristalle und verfharen zu ihrer herstellung
AU759392B2 (en) 1997-12-16 2003-04-10 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
NZ505079A (en) 1998-01-28 2003-08-29 Du Pont Pharm Co Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists
US6131106A (en) 1998-01-30 2000-10-10 Sun Microsystems Inc System and method for floating-point computation for numbers in delimited floating point representation
US20020026043A1 (en) 1998-02-06 2002-02-28 Brian Taylor Edmonds Desert hedgehog related nucleic acids and proteins
GB9805561D0 (en) 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
PA8469101A1 (es) 1998-04-09 2000-09-29 Pfizer Prod Inc Ligandos azabiciclicos de receptores 5ht1
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
ES2188095T3 (es) 1998-04-15 2003-06-16 Pfizer Prod Inc Carboxamidas heterociclicas.
ATE273970T1 (de) 1998-04-16 2004-09-15 Pfizer Prod Inc N-acyl und n-aroyl aralkylamide
WO1999059593A1 (en) 1998-05-21 1999-11-25 Eli Lilly And Company Combination therapy for treatment of depression
PL344331A1 (en) 1998-05-22 2001-11-05 Lilly Co Eli Combination therapy for treatment of refractory depression
GT199900060A (es) 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
BR9911068A (pt) 1998-05-29 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de distúrbios bipolares
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6436914B1 (en) 1998-06-30 2002-08-20 Bristol-Myers Squibb Company 2-hydroxy-3—(4-hydroxy-3-sulfonamidophenyl)—propylamines useful as beta 3 adrenergic agonists
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US6262081B1 (en) 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
CA2340180A1 (en) 1998-08-11 2000-02-24 Pfizer Products Inc. 1-aryl,-3-arylmethyl-1,8-naphthyridn-2(1h)-ones
IL125809A (en) 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
IT1304904B1 (it) 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
SK4592001A3 (en) 1998-10-16 2001-12-03 Janssen Pharmaceutica Nv Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition
US5994352A (en) 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
WO2000030446A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
WO2000031020A1 (en) 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
JP2002531502A (ja) 1998-12-11 2002-09-24 デイビス、ボニー 視床下部−下垂体−生殖腺軸変調に於けるアセチルコリンエステラーゼ阻害剤の使用
UA62015C2 (en) 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
AU2180400A (en) 1999-01-13 2000-08-01 Eli Lilly And Company A pharmaceutical combination for the treatment of depression
ES2234523T3 (es) 1999-03-01 2005-07-01 Pfizer Products Inc. Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos.
NZ513449A (en) 1999-03-01 2004-02-27 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands
US6277866B1 (en) 1999-03-03 2001-08-21 Eisai Co., Ltd. 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
WO2000059544A1 (fr) 1999-03-31 2000-10-12 Eisai Co., Ltd. Compositions stabilisees contenant des medicaments nootropes
EP1050303A3 (en) 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
EA200101110A1 (ru) 1999-05-21 2002-08-29 Пфайзер Продактс Инк. Новые фармацевтические комбинации ингибиторов nos
AU4973800A (en) 1999-06-09 2000-12-28 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
IL145998A0 (en) 1999-06-15 2002-07-25 Du Pont Pharm Co Substituted heterocycle fused gamma-carbolines
US6524616B1 (en) 1999-06-25 2003-02-25 Wake Forest University Health Services Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
JP4242048B2 (ja) 1999-09-01 2009-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−置換ピペリジン誘導体
US7091218B1 (en) 1999-09-01 2006-08-15 Eisai Co., Ltd. 4-substituted piperidine compound
WO2001021590A1 (en) 1999-09-22 2001-03-29 Schering Corporation Muscarinic antagonists
DK1088819T3 (da) 1999-09-30 2005-09-12 Pfizer Prod Inc 6-azauracilderivater som thyroidreceptorligander
CA2324813A1 (en) 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US6620802B1 (en) 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
EP1600169A3 (en) * 1999-12-01 2009-09-23 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders
CA2392992A1 (en) 1999-12-17 2001-06-21 Dupont Pharmaceuticals Company Imidazopyrimidinyl and imidazopyridinyl derivatives
JP2003517481A (ja) 1999-12-17 2003-05-27 ブリストルーマイヤーズ スクイブ カンパニー 抗精神病複素環式化合物
AU2049601A (en) 1999-12-20 2001-07-03 Eli Lilly And Company Benzofuran derivatives
EP1242419A1 (en) 1999-12-20 2002-09-25 Eli Lilly And Company Azabicyclo 3.2.1]octane derivatives
AU2251801A (en) 1999-12-20 2001-07-03 Eli Lilly And Company Piperidine derivatives and their use as serotonin receptor antagonists
ES2259619T3 (es) 1999-12-20 2006-10-16 Eli Lilly And Company Derivados de indol para el tratamiento de depresion y ansiedad.
US6835733B2 (en) 1999-12-20 2004-12-28 Eli Lilly And Company Tropane linked benzofuran derivatives
DE60013751T2 (de) 1999-12-29 2005-09-29 Pfizer Products Inc., Groton Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
BR0108134A (pt) 2000-02-17 2003-09-30 Bristol Myers Squibb Co Ligantes derivados de anilina para o receptor tiróide
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
PT1311272E (pt) 2000-03-03 2007-02-28 Eisai R&D Man Co Ltd Novos métodos utilizando inibidores de colinesterase
US20030144255A1 (en) 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
EP1265857A1 (en) 2000-03-13 2002-12-18 Eli Lilly And Company Sulfonamide derivatives
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
ATE382602T1 (de) 2000-03-31 2008-01-15 Pfizer Prod Inc Malonsäureamide sowie deren derivate als thyroidrezeptor liganden
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
ES2280375T3 (es) 2000-04-08 2007-09-16 BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO.KG Heterociclos biciclicos, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparacion.
DE60112064T2 (de) 2000-04-10 2006-06-01 Pfizer Products Inc., Groton Benzoamid-piperidin verbindungen als substanz p-antagonisten
WO2001078728A1 (fr) 2000-04-13 2001-10-25 Eisai Co., Ltd. Inhibiteurs d'acetylcholinesterases contenant des sels de 1-benzyl-pyridinium
US6620830B2 (en) 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
US6630469B2 (en) 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
US20010036949A1 (en) 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US20040229911A1 (en) 2000-05-17 2004-11-18 Pfizer Inc New pharmaceutical combinations for NOS inhibitors
JP2004509843A (ja) 2000-05-24 2004-04-02 イーライ・リリー・アンド・カンパニー うつ病の処置のための併用療法
US6893858B2 (en) 2000-05-26 2005-05-17 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
ATE391507T1 (de) 2000-06-02 2008-04-15 Pfizer Prod Inc S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
CA2411386A1 (en) 2000-06-30 2002-01-10 Eli Lilly And Company Combination therapy for treatment of psychoses
DOP2001000189A (es) 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
US20020016334A1 (en) 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US6756385B2 (en) 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
US20020049211A1 (en) 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
AU2001282913A1 (en) 2000-09-08 2002-03-22 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
AU9625501A (en) 2000-09-21 2002-04-02 Bristol Myers Squibb Co Substituted azole derivatives as inhibitors of corticotropin releasing factor
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
IL145584A0 (en) 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
US20020103198A1 (en) 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
CA2364211A1 (en) 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
WO2002059124A2 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Company Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists
RU2003121406A (ru) 2000-12-20 2004-12-27 Бристол-Маерс Сквибб Фарма Компани (Us) Производные замещенных пиразинохиноксалинов в качестве агонистов и антагонистов рецептора серотонина
EP1343791A2 (en) 2000-12-20 2003-09-17 Bristol-Myers Squibb Company Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
WO2002053153A1 (fr) 2000-12-28 2002-07-11 Daiichi Pharmaceutical Co., Ltd. Medicaments permettant de traiter et de prevenir une douleur neurologique
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
US6436938B1 (en) 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
EP1359916A4 (en) 2001-01-26 2004-04-07 Bristol Myers Squibb Co IMIDAZOLYLATED DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASE FACTOR
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US6610326B2 (en) 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
JP2004523557A (ja) 2001-02-23 2004-08-05 ジョンズ・ホプキンス・ユニバーシティ チック、振せん、および関連疾患の治療
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
WO2002072202A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
WO2002072101A1 (en) 2001-03-13 2002-09-19 Bristol-Myers Squibb Pharma Company A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
AU2002245692A1 (en) 2001-03-15 2002-10-03 David Pharmaceuticals Methods for restoring cognitive function following systemic stress
AU2002303094B2 (en) 2001-03-29 2006-11-23 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
US6777437B2 (en) 2001-03-29 2004-08-17 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
OA12504A (en) 2001-04-19 2006-05-29 Warner Lambert Co Fused bicyclic or tricyclic amino acids.
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1666886A3 (en) 2001-04-20 2006-06-21 Pfizer Products Inc. Method of identifying selective PDE10 inhibitor compounds
US20030018047A1 (en) 2001-04-20 2003-01-23 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
AU2756602A (en) 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
RU2003135424A (ru) 2001-05-14 2005-05-20 Бристол-Маерс Сквибб Фарма Компани (Us) Замещенные пиразиноны, пиридины и пиримидины в качестве лигандов кортикотропин высвобождающего фактора
EP1260221A3 (en) 2001-05-23 2002-12-18 Pfizer Products Inc. Combination treatment for depression and anxiety
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
US6566550B2 (en) 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
US6894045B2 (en) 2001-07-12 2005-05-17 Bristol-Myers Squibb Pharma Company Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
EP1408979A4 (en) 2001-07-24 2005-03-23 Bristol Myers Squibb Co R-6-HYDROXY-BUSPIRONE
EP1417203A4 (en) 2001-07-24 2005-08-10 Bristol Myers Squibb Co S-6-HYDROXY-BUSPIRONE
US8354438B2 (en) 2001-08-08 2013-01-15 Michael Chez Neurological functions
EP1284257B1 (en) 2001-08-16 2005-10-05 Pfizer Products Inc. Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter
DE60135390D1 (de) 2001-08-22 2008-09-25 Hamilton Pharmaceuticals Inc Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
WO2003020289A1 (en) 2001-08-30 2003-03-13 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
ES2253495T3 (es) 2001-09-26 2006-06-01 Pfizer Products Inc. Acidos indol carboxilicos como ligandos de receptores tiroideos.
EP1438036A2 (en) 2001-10-12 2004-07-21 Eli Lilly And Company Use of sulfonamide derivatives as pharmaceuticals compounds
RU2340600C2 (ru) 2001-10-16 2008-12-10 Мемори Фармасьютиклз Корпорейшн Производные 4-(4-алкокси-3-гидроксифенил)-2-пирролидона в качестве ингибиторов pde-4 для лечения неврологических синдромов
KR20010113584A (ko) 2001-11-08 2001-12-28 (주)시스튜디오 컴퓨터에 의한 만화 애니메이션 구현방법 및 만화애니메이션 실행데이터를 기록한 컴퓨터로 읽을 수 있는기록매체
US6673811B1 (en) 2001-11-19 2004-01-06 Neurogen Corporation 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands
WO2003043637A1 (en) 2001-11-20 2003-05-30 Bristol-Myers Squibb Pharma Company 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA02010430A (es) 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
EP1458368B1 (en) 2001-12-11 2007-11-21 Eli Lilly And Company Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20050009927A1 (en) 2002-01-23 2005-01-13 Pfizer Inc Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
US20050014848A1 (en) 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
WO2003072107A1 (en) 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Substituted pyrimidinones and pyrimidinthiones
US20040167200A1 (en) 2002-03-25 2004-08-26 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
AU2003217936A1 (en) 2002-03-28 2003-10-13 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
US6759552B2 (en) 2002-03-28 2004-07-06 Council Of Scientific And Industrial Research Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
ES2297141T3 (es) 2002-03-29 2008-05-01 EISAI R&amp;D MANAGEMENT CO., LTD. Derivados de (1-indanona)-(1,2,3,6-tetrahidropiridina).
JP2005528378A (ja) 2002-04-03 2005-09-22 イーライ・リリー・アンド・カンパニー 非定型抗精神病薬およびｍＧＬＵ２／３受容体アゴニストを組み合わせた精神病治療
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
WO2003091220A1 (en) 2002-04-26 2003-11-06 Schering Corporation Muscarinic antagonists
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
MXPA04011762A (es) 2002-05-31 2005-03-31 Lundbeck & Co As H Una combinacion de antagonista de nmda e inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US20040001895A1 (en) 2002-06-17 2004-01-01 Pfizer Inc. Combination treatment for depression and anxiety
US20030235631A1 (en) 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
US20040006135A1 (en) 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
US20040116506A1 (en) 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
US6875771B2 (en) 2002-07-26 2005-04-05 Bristol-Myers Squibb Company Pyridopyrimidine derivatives as 5-HT6 antagonists
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
US7384934B2 (en) 2002-08-05 2008-06-10 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
US7053122B2 (en) 2002-08-09 2006-05-30 Pfizer Inc Therapeutic use of aryl amino acid derivatives
GB0219154D0 (en) 2002-08-16 2002-09-25 Pfizer Ltd Diaryl compounds
GB0219153D0 (en) 2002-08-16 2002-09-25 Pfizer Ltd Substituted glycine derivatives for use as medicaments
US7115587B2 (en) 2002-08-20 2006-10-03 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
BR0314201A (pt) 2002-09-10 2005-07-12 Pfizer Prod Inc Compostos diazabicìclicos úteis no tratamento de doenças do cns e outros distúrbios
AU2003270669A1 (en) 2002-09-18 2004-04-08 Bristol-Myers Squibb Company Cyclopentyl indole derivatives
TW200418838A (en) 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
GB0223494D0 (en) 2002-10-09 2002-11-13 Neuropharma Sa Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
MXPA04006900A (es) 2002-10-24 2004-10-15 Merz Pharma Gmbh & Co Kgaa Politerapia que utiliza derivados de 1-aminociclohexano e inhibidores de acetilcolinesterasa.
RU2005112254A (ru) 2002-10-24 2006-01-20 Пфайзер Продактс Инк. (Us) Ацильные производные 5-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, обладающие нейролептической активностью
GB0225379D0 (en) 2002-10-31 2002-12-11 Pfizer Ltd Therapeutic proline derivatives
WO2004046106A1 (en) 2002-11-18 2004-06-03 Pfizer Products Inc. Dipeptidyl peptidase iv inhibiting fluorinated cyclic amides
WO2004047738A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
US6900210B2 (en) 2002-11-22 2005-05-31 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
US20040191803A1 (en) 2002-11-22 2004-09-30 Michela Gallagher Target for therapy of cognitive impairment
AU2003294441A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
EP1572112A4 (en) 2002-11-22 2006-12-06 Bristol Myers Squibb Co 3- (PYRIDINYL-PIPERAZINE-1-YL) -PHENYLETHYL AMIDES AS POTASIC CHANNEL OPENING AGENTS
AU2003294442A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
AU2003298766A1 (en) 2002-12-03 2004-06-23 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US7090985B2 (en) 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
EA200500783A1 (ru) 2002-12-11 2005-12-29 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Комбинация для лечения синдрома дефицита внимания с гиперактивностью
EP1572205A2 (en) 2002-12-11 2005-09-14 Pharmacia & Upjohn Company LLC Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
EP1592772A2 (en) 2003-01-31 2005-11-09 Pfizer Products Incorporated 5ht7 antagonists and inverse agonists
EP1605935A4 (en) 2003-03-06 2009-05-20 Celgene Corp METHODS OF USE AND COMPOSITIONS COMPRISING CYTOKINE INHIBITORY SELECTIVE MEDICAMENTS FOR TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
EP1608648B1 (en) 2003-03-12 2012-07-18 Pfizer Products Inc. Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
US20040191334A1 (en) 2003-03-24 2004-09-30 Pang-Chui Shaw Use of transhinone derivates as cholinesterase inhibitors in treating related diseases
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
MXPA05010293A (es) 2003-03-27 2005-11-17 Pfizer Prod Inc 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas.
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US7041671B2 (en) 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
US7034023B2 (en) 2003-04-04 2006-04-25 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056920B2 (en) 2003-04-04 2006-06-06 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
BRPI0409307A (pt) 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
US7030145B2 (en) 2003-04-18 2006-04-18 Bristol-Myers Squibb Company Pyridinyl derivatives for the treatment of depression
US7112585B2 (en) 2003-04-18 2006-09-26 Bristol-Myers Squibb Company Pyrimidine derivatives as corticotropin releasing factor inhibitors
MXPA05011387A (es) 2003-04-23 2005-12-01 Pharmacia & Upjohn Co Llc Pirimidinonas y pirimidinotionas sustituidas.
GB0309440D0 (en) 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CA2523072A1 (en) 2003-05-07 2004-11-18 Pharmacia & Upjohn Company Llc Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists
WO2004099148A1 (en) 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Substituted pyrimidine derivatives
CA2525866A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
MXPA05012320A (es) 2003-05-16 2006-01-30 Pfizer Prod Inc Tratamientos de trastornos bipolares y sintomas asociados.
RU2005135454A (ru) 2003-05-16 2006-06-27 Пфайзер Продактс Инк. (Us) Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
WO2004100956A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
MXPA05012538A (es) 2003-05-23 2006-02-22 Otsuka Pharma Co Ltd Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo.
US7101881B2 (en) 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
BRPI0410561A (pt) 2003-06-18 2006-06-20 Pfizer Prod Inc lactamas de piperazinileteroarilóxi-n-arill e de piperazinilarilóxi
BRPI0411122A (pt) 2003-06-27 2006-07-18 Pfizer Prod Inc pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
EP1641454B1 (en) 2003-06-27 2008-10-01 Pfizer Products Inc. Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors
US20050070577A1 (en) 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
WO2005013961A1 (en) 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
TW200510324A (en) 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2005019168A2 (en) 2003-08-20 2005-03-03 Pfizer Products Inc. Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
CA2542339A1 (en) 2003-09-09 2005-03-17 Pfizer Products Inc. Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
US20060270656A1 (en) 2003-09-09 2006-11-30 Eli Lilly And Company Substituted piperazines of azepines, oxazepines and thiazepines
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
CA2541458C (en) 2003-10-08 2011-09-20 Eli Lilly And Company Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
CA2541162A1 (en) 2003-10-08 2005-04-21 Pfizer Inc. Fused lactam compounds
US20050080100A1 (en) 2003-10-09 2005-04-14 Pfizer Inc Pyridylamino compounds and methods of use thereof
JP2007508367A (ja) 2003-10-16 2007-04-05 ファイザー・プロダクツ・インク ３−アザビシクロ［３．１．０］ヘキサン誘導体の製造方法
DK1675591T3 (da) 2003-10-16 2011-11-14 Neurosearch As Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer
CN1898201A (zh) 2003-10-21 2007-01-17 森蒂有限公司 可抑制胆碱酯酶和释放药理学活性试剂的氨基甲酸酯
WO2005051488A1 (en) 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
ATE473967T1 (de) 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
WO2005053701A1 (en) 2003-11-26 2005-06-16 Pfizer Products Inc. Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
EP1706376B1 (en) 2003-12-02 2009-03-04 UCB Pharma, S.A. Imidazole derivatives, processes for preparing them and their uses
WO2005060949A2 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
JP2007513995A (ja) 2003-12-15 2007-05-31 ファイザー・プロダクツ・インク アラルキルおよびアラルキリデン複素環式ラクタムおよびイミド
US20050227980A1 (en) 2003-12-15 2005-10-13 Pfizer Inc. Aralkyl and aralkylidene heterocyclic lactam and imides
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
JP2007516275A (ja) 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
US20050171095A1 (en) 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
ES2383115T3 (es) 2004-01-09 2012-06-18 Eli Lilly And Company Compuestos de tiofeno y furano
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
WO2005082372A1 (en) 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
BRPI0507250A (pt) 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
JP2007522200A (ja) 2004-02-13 2007-08-09 ファイザー・プロダクツ・インク 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ
EP1727538A2 (en) 2004-02-13 2006-12-06 Neuromolecular Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
EA011011B1 (ru) 2004-02-25 2008-12-30 Эли Лилли Энд Компани 6-ЗАМЕЩЁННЫЕ 2,3,4,5-ТЕТРАГИДРО-1H-БЕНЗО[d]АЗЕПИНЫ В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРОВ 5-HT
GB0405200D0 (en) 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
US20060148807A1 (en) 2004-03-12 2006-07-06 Pfizer Inc Pyrrolo[1,2b]pyridazine compounds and their uses
US20060166998A1 (en) 2004-03-12 2006-07-27 Pfizer Inc Pyrrolo[1,2-B]pyridazine compounds and their uses
AP2006003726A0 (en) 2004-03-17 2006-10-31 Pfizer Prod Inc Novel benzyl(idene)-lactam derivatives
WO2005092009A2 (en) 2004-03-19 2005-10-06 Axonyx, Inc. Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
WO2005102272A2 (en) 2004-04-21 2005-11-03 Pfizer Products Inc. Sustained-release dosage forms for cabergoline
JP2007533740A (ja) 2004-04-22 2007-11-22 イーライ リリー アンド カンパニー Ｂａｃｅ阻害剤としてのアミド
US20050245543A1 (en) 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
WO2005107808A2 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
BRPI0511195A (pt) 2004-05-21 2007-12-04 Pfizer Prod Inc tetraidronaftilpiperazinas como antagonistas da 5-ht1b, agonistas inversos e agonistas parciais
WO2005113535A2 (en) 2004-05-21 2005-12-01 Pfizer Products Inc. Pyrazinylmethyl lactam derivatives
US20070264358A1 (en) * 2004-06-04 2007-11-15 Wittlin William A Methods and Compositions for Treating Mood Disorder
US20070212428A1 (en) 2004-06-04 2007-09-13 Mood Management Sciences, Inc. Methods and compositions for treating mood disorder
US7612215B2 (en) 2004-06-11 2009-11-03 Ucb Pharma, S.A. Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
MXPA06015267A (es) 2004-06-22 2007-03-15 Pfizer Prod Inc Antagonistas diazabiciclicos del receptor histamina-3.
MXPA06014473A (es) 2004-06-25 2007-03-01 Pfizer Prod Inc Piridil piperazinas para el tratamiento de trastornos de sistema nervioso central.
US7618980B2 (en) 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
MX2007000763A (es) 2004-07-21 2007-03-28 Pfizer Prod Inc Antagonistas del receptor 3 de la histamina.
PA8640801A1 (es) 2004-08-09 2006-08-03 Warner Lambert Co Nuevos inhibidores de la recaptacion de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central
BRPI0514820A (pt) 2004-09-01 2008-06-24 Pfizer Prod Inc antagonistas de receptor de histamina-3 amina azabicìclicos
EP1791807A1 (en) 2004-09-10 2007-06-06 Pfizer Products Incorporated Therapeutic diphenyl ether ligands
JP2008512440A (ja) 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ジアザビシクロ化合物含有ベンゾイソオキサゾールを用いる気分障害の治療方法
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US20060069087A1 (en) 2004-09-27 2006-03-30 Pfizer Inc Histamine-3 receptor antagonists
WO2006040688A2 (en) 2004-10-12 2006-04-20 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
CA2581188A1 (en) 2004-10-15 2006-04-20 Pfizer Inc. Treatment of bipolar disorders and associated symptoms
AU2005295860A1 (en) 2004-10-18 2006-04-27 Eli Lilly And Company 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mGluR3 receptor antagonists
WO2006044176A1 (en) 2004-10-18 2006-04-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2006060082A1 (en) 2004-10-22 2006-06-08 THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors
WO2006046131A1 (en) 2004-10-29 2006-05-04 Pfizer Products Inc. Tetralin histamine-3 receptor antagonists
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
CA2587461A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
CA2587826A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
JP4130219B2 (ja) 2004-11-29 2008-08-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 治療用のピラゾロ［３，４−ｂ］ピリジンおよびインダゾール
ATE395348T1 (de) 2004-12-07 2008-05-15 Pfizer Prod Inc 1,2,3,3a;8,8a-hexahydro-2,7a- diazacyclopenta(a)inden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
EP2425845A1 (en) 2004-12-23 2012-03-07 Voyager Pharmaceutical Corporation Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease
WO2006070394A1 (en) 2004-12-28 2006-07-06 Council Of Scientific And Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
PL1838716T3 (pl) 2005-01-05 2011-09-30 Lilly Co Eli Dihydrat embonianu olanzapiny
AU2005325930B2 (en) 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
US7238702B2 (en) 2005-02-10 2007-07-03 Bristol-Myers Squibb Company Dihydroquinazolinones as 5HT modulators
FR2881618B1 (fr) 2005-02-10 2007-04-13 Centre Nat Rech Scient Utilisation de composes derives de pyrimidinetrione en tant qu'inhibiteurs de l'acetylcholinesterase, compositions contenant ces derives et leurs utilisations en tant qu'insecticides
EP1853578A1 (en) 2005-02-15 2007-11-14 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
US20070298098A1 (en) 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006090272A1 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006123357A2 (en) 2005-02-22 2006-11-23 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
JP2008534522A (ja) 2005-03-30 2008-08-28 ジェンファーム インク 医薬組成物のための複合ステップ製造方法
EA200701856A1 (ru) 2005-04-01 2008-02-28 Уорнер-Ламберт Компани Ллс Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
WO2006106416A1 (en) 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
ES2520015T3 (es) 2005-04-08 2014-11-11 Pfizer Products Inc. [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
US20080305161A1 (en) 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US7741358B2 (en) 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US20060241144A1 (en) 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
WO2006116401A1 (en) 2005-04-28 2006-11-02 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
MX2007015052A (es) * 2005-05-31 2008-01-18 Orexigen Therapeutics Inc Metodos y composiciones para manejar trastornos psicoticos.
US8183241B2 (en) 2005-06-01 2012-05-22 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives
EP1731149A1 (en) 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
CA2607499C (en) 2005-06-22 2010-11-30 Pfizer Products Inc. Histamine-3 receptor antagonists
US20070015763A1 (en) 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
EP1910361A2 (en) 2005-07-28 2008-04-16 Brystol-Myers Squibb Company Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists
WO2007019312A2 (en) 2005-08-03 2007-02-15 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2007017750A1 (en) 2005-08-08 2007-02-15 Pfizer Products Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
WO2007026219A2 (en) 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
BRPI0615048A2 (pt) 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
CA2619566C (en) 2005-09-01 2013-08-13 Eli Lilly And Company 6-substituted-2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
SI1926712T1 (sl) 2005-09-01 2010-01-29 Lilly Co Eli 6-substituirani 2,3.4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja
WO2007028132A2 (en) 2005-09-01 2007-03-08 Eli Lilly And Company 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
US20090215857A1 (en) 2005-09-13 2009-08-27 Pfizer Products Inc. Therapeutic Pyrrolidines
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
JP2009518333A (ja) 2005-12-07 2009-05-07 ユセベ ファルマ ソシエテ アノニム キサンチン誘導体、その調製方法及びその使用
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
US20100222353A1 (en) 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20090023756A1 (en) 2006-02-23 2009-01-22 Pfizer Inc Substituted quinazolines as pde10 inhibitors
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
CN101437510B (zh) 2006-03-20 2012-12-05 科学与工业研究会 用作乙酰胆碱酯酶抑制剂的药物组合物
US20070224636A1 (en) 2006-03-24 2007-09-27 Pfizer Inc Pyrrolo[1,2b]pyridazine compounds and their uses
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
CA2650976A1 (en) 2006-05-02 2007-11-15 Pfizer Products Inc. Bicyclic heteroaryl compounds as pde10 inhibitors
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
ES2444009T3 (es) 2006-06-08 2014-02-21 Ucb Pharma, S.A. Co-cristales de pirrolidinonas
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080014264A1 (en) 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
ATE496894T1 (de) 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
WO2008015516A1 (en) 2006-07-28 2008-02-07 Pfizer Products Inc. Fused tricyclic heterocycles for the treatment of schizophrenia
US20080045512A1 (en) 2006-08-09 2008-02-21 Pfizer Inc. Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2008020306A2 (en) 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
EP2051696A2 (en) 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
EP2114897A2 (en) 2006-09-12 2009-11-11 Pfizer Products Inc. Benzimidazolone derivatives
WO2008062446A2 (en) 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
WO2008036846A2 (en) 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TW200825067A (en) 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
US8247563B2 (en) 2006-12-11 2012-08-21 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2008074896A1 (en) 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
WO2008084324A1 (en) 2007-01-04 2008-07-17 Pfizer Products Inc. Naphthyridinone compound
CN101631545B (zh) 2007-01-22 2013-03-13 辉瑞产品公司 治疗性化合物的甲苯磺酸盐及其药物组合物
US8101782B2 (en) 2007-02-02 2012-01-24 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
FR2912056B1 (fr) 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
MX2009008546A (es) 2007-02-07 2009-10-08 Pfizer Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)carbaldehido como inhibidores de la proteina quinasa c.
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体
EP2142554B1 (en) 2007-04-25 2015-01-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2008132139A2 (en) 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
US7846930B2 (en) 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
RU2339620C1 (ru) 2007-07-09 2008-11-27 Общество С Ограниченной Ответственностью "Фармвинг" Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции
US20100168174A1 (en) 2007-07-13 2010-07-01 Eisai R&D Management Co., Ltd. Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
US20090030403A1 (en) 2007-07-27 2009-01-29 Leyde Kent W Methods and Systems for Attenuating the Tolerance Response to a Drug
WO2009038412A2 (en) 2007-09-21 2009-03-26 Lg Life Sciences, Ltd. Beta-secretase inhibiting compounds
US20090176740A1 (en) 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
WO2009071988A1 (en) 2007-12-07 2009-06-11 Pfizer Inc. Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-flu0r0-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide
US20100297181A1 (en) * 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
DK2252581T3 (da) 2008-01-22 2012-07-16 Lilly Co Eli Kappa-selektiv opioidreceptorantagonist
WO2009098576A1 (en) 2008-02-05 2009-08-13 Pfizer Inc. Pyridinyl amides for the treatment of cns and metabolic disorders
WO2009109547A1 (en) 2008-03-03 2009-09-11 Ucb Pharma, S.A. Pharmaceutical solutions, process of preparation and therapeutic uses
WO2009127944A1 (en) 2008-04-17 2009-10-22 Pfizer Inc. Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
CN102119029B (zh) 2008-04-22 2013-03-13 伊莱利利公司 作为cb-1配体的1，5-二苯基-吡咯烷-2-酮化合物
CN102007121B (zh) 2008-04-22 2013-08-14 伊莱利利公司 作为cb-1配体的1，5-二苯基-吡咯烷-2-酮化合物
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
WO2010002869A1 (en) 2008-07-01 2010-01-07 Concert Pharmaceuticals, Inc. 2-oxo-1-pyrrolidine derivatives
JP2010024156A (ja) 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
TW201006801A (en) 2008-07-18 2010-02-16 Lilly Co Eli Imidazole carboxamides
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
DK3260118T3 (da) 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
US20100113465A1 (en) 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
US9125898B2 (en) 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
WO2010057088A2 (en) 2008-11-17 2010-05-20 Auspex Pharmaceuticals, Inc. Pyrrolidinyl modulators of nicotinic acetylcholine receptors
CA2741041C (en) 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
CA2741839A1 (en) 2008-11-21 2010-05-27 Pfizer Inc. 1-oxa-8-azaspiro [4,5] decane-8-carboxamide compounds as faah inhibitors
US20100172979A1 (en) 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
CN102300562A (zh) 2009-01-29 2011-12-28 Ucb医药有限公司 含有2-氧代-1-吡咯烷衍生物的药物组合物
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
US8563583B2 (en) 2009-03-09 2013-10-22 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2406233B1 (en) 2009-03-09 2013-11-13 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
WO2010111080A2 (en) 2009-03-27 2010-09-30 Eli Lilly And Company Optimized treatment of schizophrenia
US8846411B2 (en) 2009-06-11 2014-09-30 Microgenics Corporation Derivatives, reagents, and immunoassay for detecting levetiracetam
EA201190287A1 (ru) 2009-06-18 2012-06-29 Пфайзер Инк. Бициклические и трициклические соединения в качестве ингибиторов kat ii
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function
CN101647789B (zh) 2009-09-01 2011-08-17 天津药物研究院药业有限责任公司 左乙拉西坦缓释微丸胶囊制剂
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
DK2501704T3 (da) 2009-11-16 2013-10-14 Lilly Co Eli Spiropiperidinforbindelser som oral-1-receptorantagonister
UA107943C2 (en) 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
JO2978B1 (en) 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
WO2011143721A1 (en) 2010-05-21 2011-11-24 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating neurodegenerative disorders
MX2013000138A (es) 2010-07-08 2013-03-05 Pfizer Amidas de piperidinil pirimidina como abridores de canales de potasio de kv7.
US20130184294A1 (en) 2010-09-21 2013-07-18 Pfizer Inc. Pyrimidones for Treatment of Potassium Channel Related Diseases
WO2012056402A2 (en) 2010-10-26 2012-05-03 Alpharma Pharmaceuticals, Llc Formulations and methods for attenuating respiratory depression induced by opioid overdose
KR20120055313A (ko) 2010-11-23 2012-05-31 주식회사 바이오파마티스 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
SG190246A1 (en) 2010-12-01 2013-06-28 Pfizer Kat ii inhibitors
EP2646443B1 (en) 2010-12-01 2014-09-24 Pfizer Inc Kat ii inhibitors
WO2012109491A1 (en) 2011-02-09 2012-08-16 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2681218A1 (en) 2011-02-23 2014-01-08 Pfizer Inc IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DE102011103270A1 (de) 2011-05-26 2012-11-29 Stada Arzneimittel Ag Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014144546A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositons for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Also Published As

Publication number Publication date
US20180125818A1 (en) 2018-05-10
EP2919788A1 (en) 2015-09-23
WO2014078568A1 (en) 2014-05-22
US10154988B2 (en) 2018-12-18
EP2919788A4 (en) 2016-05-25
JP2018090609A (ja) 2018-06-14
EP3610890A1 (en) 2020-02-19
US10624875B2 (en) 2020-04-21
JP2015537003A (ja) 2015-12-24
CA2891122C (en) 2021-07-20
JP6440625B2 (ja) 2018-12-19
US20140206667A1 (en) 2014-07-24
US20150313876A1 (en) 2015-11-05
CA2891122A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
HK1215170A1 (zh) 治療精神分裂症的方法和組合物
HK1209798A1 (zh) 用於治療癌症的組合物和方法
EP2836482A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2890720A4 (en) COMPOSITIONS AND METHODS OF TREATING CANCER
IL234989B (en) Compounds and preparations containing them for the treatment of cancer
HK1251796A1 (zh) 治療糖尿病的方法和組合物
HK1204988A1 (zh) 用於預防或治療眼科病狀的方法和組合物
IL269166A (en) Methods and preparations for treating inflammation
DK3292875T3 (en) Compositions and methods for treating diseases
EP2895606A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS (ALS)
IL232648A0 (en) Preparations and methods for treating glioma
EP2922534A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
HK1216854A1 (zh) 用於治療癌症的組合物和方法
EP2931280A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1
HK1207561A1 (zh) 用於治療肝細胞癌的組合物和方法
HK1209040A1 (zh) 用於治療前庭毒性的方法
EP2841102A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2822593A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP2800763A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
EP2906199A4 (en) METHOD AND COMPOSITION FOR TREATING PSORIASIS